Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of TQB3616 plus endocrine therapy versus placebo plus endocrine therapy as adjuvant treatment for HR-positive, HER2-negative breast cancer
CTR20230155Phase 3Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of culmerciclib in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Mar 2023; status: active.
02
Drugs
culmerciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20230155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230155.